MLN4924 Suppresses Acute Myeloid Leukemia Progression by LINC01128-Driven Epigenetic Reactivation of TRIM58
Open Access
- 1 October 2025
- journal article
- research article
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 9439-9456
Abstract
Purpose: The aim of this study was to elucidate the molecular mechanism by which MLN4924 affects the progression of acute myeloid leukemia (AML) by regulating TRIM58 DNA methylation. Patients and Methods: Gene expression was analyzed by RT-qPCR and Western blot, while methylation changes were assessed via Methylation-sensitive restriction enzyme-quantitative PCR. Differentially expressed lncRNAs were identified through RNA sequencing. Subcellular localization was determined via nuclear-cytoplasmic fractionation-PCR. Protein-DNA/RNA interactions were analyzed by chromatin immunoprecipitation and RNA immunoprecipitation, respectively. In vivo experiments were conducted using a xenograft model, with tumor protein expression evaluated by immunohistochemistry. Results: TRIM58 downregulation in AML correlated with promoter hypermethylation, reversible by MLN4924 treatment. Functional studies demonstrated TRIM58 mediated MLN4924-induced apoptosis through AKT pathway inhibition. While MLN4924 upregulated the tumor-suppressive lncRNA LINC01128, its overexpression recapitulated TRIM58-mediated anti-leukemic effects, including expansion arrest, apoptosis induction, and BAX/BCL-2 axis modulation. Mechanistically, nuclear-localized LINC011128 functionally interacted with DNMT1 to mediate TRIM58 promoter demethylation, establishing an epigenetic regulatory axis. Rescue experiments revealed TRIM58 knockdown attenuated MLN4924’s suppression of AKT phosphorylation and associated pro-apoptotic effects. Conclusion: In this study, we show that MLN4924 can upregulate LINC01128, which binds to and segregates DNMT1, thereby inhibiting methylation modification of the TRIM58 and ultimately suppressing AML.Keywords
This publication has 39 references indexed in Scilit:
- BCL7A inhibits the progression and drug-resistance in acute myeloid leukemiaDrug Resistance Updates, 2024
- AML treatment: conventional chemotherapy and emerging novel agentsTrends in Pharmacological Sciences, 2024
- METTL3‐stabilized super enhancers‐lncRNA SUCLG2‐AS1 mediates the formation of a long‐range chromatin loop between enhancers and promoters of SOX2 in metastasis and radiosensitivity of nasopharyngeal carcinomaClinical and Translational Medicine, 2023
- LncRNA-ZFAS1 Promotes Myocardial Ischemia-Reperfusion Injury Through DNA Methylation-Mediated Notch1 Down-Regulation in MiceJACC: Basic To Translational Science, 2022
- LncRNA PVT1 mediates the progression of liver necroptosis via ZBP1 promoter methylation under nonylphenol exposureScience of The Total Environment, 2022
- Quantitative analyses for effects of neddylation on CRL2VHL substrate ubiquitination and degradationProtein Science, 2021
- UBE2M Is a Stress-Inducible Dual E2 for Neddylation and Ubiquitylation that Promotes Targeted Degradation of UBE2FMolecular Cell, 2018
- Decreased SCIN expression, associated with promoter methylation, is a valuable predictor for prognosis in acute myeloid leukemiaMolecular Carcinogenesis, 2018
- Regulation of Bax/mitochondria interaction by AKTFEBS Letters, 2015
- DNA methylation as a pathogenic event and as a therapeutic target in AMLCancer Treatment Reviews, 2011